Overview: Aiming to curb rising costs for GLP-1 medications The Trump administration announced a landmark set of deals on Thursday with the pharmaceutical giants Novo Nordisk and Eli Lilly. The agreements are designed to reduce the out-of-pocket and list prices of GLP-1 drugs—medications increasingly prescribed for weight management and diabetes—especially for Medicare beneficiaries and other…